Life Sciences

  • August 28, 2026

    AI-Bolstered Drug Co. Hits Ch. 11 With $105M Debt

    A company that uses artificial intelligence to explore new uses for existing drugs entered bankruptcy in Delaware with over $104 million in debt and a stalking horse bidder.

  • August 28, 2026

    Parse Owes $4.9M In Cell Analysis Patent Case, Jury Finds

    A Delaware federal jury on Friday put Parse Biosciences Inc. on the hook for $4.9 million after finding that the biotechnology company infringed a trio of Roche Sequencing Solutions Inc. patents covering a way of detecting target molecules in cell samples.

  • August 28, 2026

    Rising Star: Ropes & Gray's Ray Grant

    Ray Grant of Ropes & Gray LLP advised Bain Capital portfolio company Tanabe Pharma Corp. in a $2.5 billion sale of the global rights to a treatment for ALS, earning him a spot among the life sciences law practitioners under age 40 honored by Law360 as Rising Stars.

  • August 28, 2026

    Medical Marijuana Industry Grapples With DEA's New Role

    After years of allowing the state-sanctioned medical marijuana industry to operate without interference, the U.S. Drug Enforcement Administration is stepping in to regulate a drug it once treated exclusively as contraband, but attorneys and regulators say the cannabis industry's interactions with the agency are off to a rocky start.

  • August 28, 2026

    Fla. Says PBMs Fixed Prices For Prescription Drugs

    Florida's attorney general on Thursday sued two competing pharmacy benefit managers for allegedly colluding to fix prescription drug reimbursement rates to pharmacies, which the state said threatens Floridians' access to affordable medications.

  • August 28, 2026

    4 Arguments For Benefits Attys To Watch In September

    The Fifth Circuit will weigh Louisiana's bid to block telehealth access to the abortion drug mifepristone, while the Fourth Circuit will hear Lockheed Martin's challenge to a trial court decision that kept a pension de-risking suit alive. Here's a look at these and other argument sessions that should be on benefits attorneys' radar next month.

  • August 27, 2026

    PBMs Hammer Opioid Judge In Last-Ditch Gambit At 6th Circ.

    An Ohio federal judge knowingly flouted a Sixth Circuit rebuke by forcing two of the largest remaining defendants in multidistrict opioid litigation to either "settle for enormous sums or litigate for years hundreds of cases," says a Thursday petition urging the appeals court to intervene.

  • August 27, 2026

    Albertsons Loses Bid For Midtrial Win In Wash. Opioid Case

    Albertsons can't escape the state of Washington's lawsuit accusing the pharmacy chain and its Safeway subsidiary of contributing to the state's opioid crisis, a state judge ruled Thursday in denying the company's bid to dismiss the case midtrial.

  • August 27, 2026

    Mead Johnson Nutrition Head Defends Formula In MDL Trial

    Mead Johnson's head of nutrition testified Thursday in a trial over whether its preterm infant formula led to a newborn's serious and ultimately fatal gut illness, saying she had no reasons to worry about the product's safety but acknowledging it carries a higher risk for the disease than human breast milk.

  • August 27, 2026

    5th Circ. Backs FDA, Pharma Cos. In GLP-1 Shortage Fight

    The U.S. Food and Drug Administration did not unlawfully remove blockbuster GLP-1 medications made by Eli Lilly & Co. and Novo Nordisk from the national drug shortage list, the Fifth Circuit ruled Thursday, handing a loss to compounding pharmacies that produce copycat doses of the drugs.

  • August 27, 2026

    Guardant Suits Against Tempus AI Clear Dismissal Bids

    A Delaware federal judge has refused to throw out litigation accusing Tempus AI Inc. of infringing Guardant Health Inc. patents covering technology used to analyze cancer-related genetic data and help guide testing and treatment.

  • August 27, 2026

    23andMe Judge Slows Estimation Of Calif. Data Breach Claim

    A Missouri bankruptcy judge ruled Thursday he would split a process for dealing with data breach claims brought by the state of California against 23andMe into two stages, saying he would first decide whether the bankruptcy trust for the DNA testing company should be allowed to estimate the state's claims for damages.

  • August 27, 2026

    Mich. Hospitals Defend CVS 340B Drug Savings Suit

    University of Michigan Hospitals and Health Centers urged a Michigan federal judge Wednesday to preserve its suit claiming that CVS Health Corp. diverted millions of dollars earmarked for indigent healthcare to itself, saying the conduct clearly amounts to a racketeering scheme.

  • August 27, 2026

    USPTO Sets Radiation Monitoring Patent Order As Informative

    The U.S. Patent and Trademark Office has added weight to a Patent Trial and Appeal Board order from earlier this year that undid a decision rejecting an RNA patent application.

  • August 27, 2026

    Rising Star: Goodwin's Heath Ingram

    Heath Ingram of Goodwin Procter LLP advised Avadel Pharmaceuticals on its launch of a U.S. Food and Drug Administration-approved narcolepsy drug and then its $2.37 billion sale to fellow Irish drugmaker Alkermes, earning him a spot among life sciences attorneys under age 40 honored by Law360 as Rising Stars.

  • August 26, 2026

    5th Circ. Upholds Drug Negotiations In Blow To Big Pharma

    Medicare's landmark program of drug price negotiations doesn't flout constitutional provisions involving the separation of powers, due process or excessive fines, the Fifth Circuit ruled late Wednesday, delivering a fresh blow to the pharmaceutical industry's campaign to tee up U.S. Supreme Court review.

  • August 26, 2026

    Eton's Galzin TM And False Ad Suit Survives Dismissal Bid

    Eton Pharmaceuticals can proceed with trademark infringement and false advertising claims accusing Extreme V of marketing a dietary supplement as a Wilson disease treatment, with a Michigan federal judge finding that Extreme V's defenses and factual challenges could not dispose of the case at the pleading stage.

  • August 26, 2026

    Humana Keeps Conspiracy Claims Against Mylan, Lannett

    A federal judge refused to grant Mylan and Lannett summary judgment on claims in Humana's suit alleging a conspiracy to fix the prices of generic drugs ahead of its bellwether trial, calling it premature and noting that the other parties did not join the motion.

  • August 26, 2026

    2nd Circ. Says Shield Law Covers Doctor In COVID Death Suit

    The Second Circuit on Wednesday affirmed the dismissal of a Connecticut estate's malpractice suit alleging a doctor negligently prescribed high doses of prednisone to an elderly COVID-19 patient who subsequently died of organ failure, finding the suit is barred under the Public Readiness and Emergency Preparedness Act.

  • August 26, 2026

    Idaho Abortion Ban Relief Narrowed To 1 Doctor

    An Idaho federal judge walked back his recent order barring the state from enforcing its near-total abortion ban in certain health-related circumstances, finding that precedent in the U.S. Supreme Court supported a narrower injunction.

  • August 26, 2026

    Rising Star: Sullivan & Cromwell's RuiHui 'Rachel' Yu

    RuiHui "Rachel" Yu of Sullivan & Cromwell LLP helped Chinese biotechnology company MediLink Therapeutics craft an agreement granting Roche exclusive rights to commercialize its lead antibody-drug conjugate outside China, earning her a spot among life sciences attorneys under age 40 honored by Law360 as Rising Stars.

  • August 26, 2026

    Pot Distributor Again Files Counterclaims In Contract Dispute

    A cannabis distributor has filed renewed counterclaims against its former consulting partner and a rival distributor, alleging that the rival deliberately interfered with an exclusivity agreement with the consulting partner.

  • August 25, 2026

    Albertsons Witness Says Co.'s Opioid Policies Beat Standards

    Albertsons' pharmacy policies for reviewing potentially suspicious opioid prescriptions "met or exceeded" the standard of care, an expert witness for the company testified Tuesday, on the 26th day of a bench trial in Washington's case accusing the pharmacy chain of fueling the state's opioid epidemic.

  • August 25, 2026

    Ex-Taro Exec Slips Some Generics Price-Fixing Claims

    A Connecticut federal judge gave a former Taro Pharmaceuticals USA Inc. marketing executive a partial victory in generic drug price-fixing litigation, tossing several claims by state attorneys general but allowing others to proceed after finding that a jury could conclude he joined certain conspiracies.

  • August 25, 2026

    Health Exec Says CFO, Atty Knew Wage Claim Was Wrong

    A former corporate officer has sued his ex-colleague and the colleague's attorney in Connecticut state court, alleging they named him as a personal defendant in a federal wage lawsuit without any factual basis and with the intent to pressure his company into settling claims it disputed.

Expert Analysis

  • Fed. Circ. In July: Meeting The Enablement Requirement

    Author Photo

    The Federal Circuit's decision in Wyeth v. AstraZeneca last month exemplifies when a generalized conception of an invention is insufficient to enable the full scope of asserted patent infringement claims, and may lead to more enablement challenges, say attorneys at Knobbe Martens.

  • Series

    Taekwondo Makes Me A Better Lawyer

    Author Photo

    Taekwondo has taught me to recognize when to fight for a position and when to focus on finding a solution, and that the best outcomes are often achieved by solving problems — all of which has improved my work as a bankruptcy lawyer, mediator and Subchapter V trustee, says Amy Denton Mayer at Berger Singerman.

  • Why AI Diligence Is Especially Key In IP Practice

    Author Photo

    In light of recent federal court sanctions against intellectual property litigators for filing work product generated by artificial intelligence without verification, it's important to consider the unique risks and consequences that can arise from overreliance on AI, which poses less visible risks in IP matters, says Stephen Ball at Husch Blackwell.

  • How 'Most Favored Nation' Regime Affects Biopharma Deals

    Author Photo

    As M&A activity surges in the biopharma space, companies will need to account for the Trump administration's most-favored-nation pricing proposals — durable in concept, if unsettled in detail — when drafting deals, say attorneys at Gibson Dunn.

  • What To Know As Legal Duty To Consider AI Takes Shape

    Author Photo

    While the U.K. Jurisdiction Taskforce’s recent statement on liability for artificial intelligence harms is nonbinding for both U.K. and U.S. lawyers, it highlights the importance of being able to distinguish between the availability of a tool and a professional obligation to use it, say Jonny Frank and Michael Costa at StoneTurn.

  • NC Dental Review Change Counters Tougher National Trend

    Author Photo

    North Carolina’s elimination of its prior review requirement for dental management agreements departs sharply from the national trend toward expanded corporate practice of medicine oversight, but stakeholders should not view this regulatory shift as a relaxation of compliance expectations, say attorneys at Holland & Knight.

  • NY Bill Would Boost Litigation Risk For Cosmetics Cos.

    Author Photo

    The Beauty Justice Act, now pending in the New York Legislature, would not only present compliance challenges for companies making cosmetics and personal care products, but could also be used by private plaintiffs to bring consumer fraud, false advertising, toxic exposure and product liability claims, says Kadeejah Kelly-Previl at Faegre Drinker.

  • How To Structure Protective Order AI Provisions In IP Disputes

    Author Photo

    A survey of protective orders in recent intellectual property litigation reveals best practices for drafting provisions on artificial intelligence use that maximize IP protection while balancing enforceability with efficient discovery, say Matthew Stephens and Bryce Tabbut at MoFo.

  • Appellate Vape Rulings May Expand State Regulation Powers

    Author Photo

    Two recent federal appeals courts decisions rejecting Federal Food, Drug and Cosmetic Act preemption challenges to state electronic nicotine delivery systems directory laws signal an emerging appellate consensus that could significantly expand states' power to regulate vaping product sales where federal enforcement falls short, say attorneys at Troutman.

  • 5 Lessons For VC Investors From Del. IPO Ruling

    Author Photo

    The Delaware Court of Chancery's recent dismissal of Rostov v. Alcon Research, a derivative action over a proposed initial public offering, provides multiple practice pointers for venture capital investors, including the importance of precisely worded corporate documents and pleading a coherent theory of corporate harm, says Ben Dubin at VC Expert Services.

  • Fed. Circ. Rulings Emphasize Adjudicative Access And Review

    Author Photo

    Decisions from the Federal Circuit's 2026 docket indicate that the court is increasingly paying attention to whether tribunals possess authority to act, meaning practitioners will need to properly address procedural hurdles before they can argue the merits of a case, say attorneys at Reichman Jorgensen.

  • Series

    Being In A Band Made Me A Better Lawyer

    Author Photo

    Playing shows in storied New York City venues and rehearsing with my bandmates in poorly ventilated rooms helped develop the professional qualities I rely on as a litigator, including an ability to collaborate with strong-minded equals and the determination to treat each client with singular focus, says Eliad Shapiro at Herrick Feinstein.

  • 10th Circ. Ruling Undermines False Ad 'Two Clicks' Rule

    Author Photo

    The Tenth Circuit’s recent ruling in KetoNatural Pet Foods v. Hill's Pet Nutrition substantially challenges a long-standing assumption that a company can avoid responsibility for promotional claims simply because the consumer encountered them by clicking a hyperlink to a third-party website, say attorneys at Venable.

  • How Drug Trial Prediction Markets Pose Insider Trading Risks

    Author Photo

    Multiple prediction market platforms have recently announced plans to offer event contracts related to clinical trial outcomes and regulatory decisions, creating new insider trading risks by expanding the group of people possessing related material nonpublic information far beyond traditional corporate insiders, say attorneys at King & Spalding.

  • Mich. Ruling Gives Consumer Protection Law Its Teeth Back

    Author Photo

    The Michigan Supreme Court's recent decision in Attorney General v. Eli Lilly, overruling key holdings in two earlier cases, means that Michigan businesses can no longer defeat allegations of deceptive conduct under the state's consumer protection law simply by pointing to any governmental regulation of the business, say attorneys at DiCello Levitt.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here